Disproportionality analysis of drug-associated progressive multifocal leukoencephalopathy using spontaneous reports: A 20-year signal detection study based on the FAERS database
PLOS One · 03.02.2026 · 21 (2) · e0341855
DOI: 10.1371/journal.pone.0341855 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, online erschienen am 03.02.2026. Verfasst von Hailong Wang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Tongji Shanxi Hospital, Taiyuan, China. Hauptthemen laut MEDLINE: Leukoencephalopathy, Progressive Multifocal, Adverse Drug Reaction Reporting Systems. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shanxi Provincial Department of Science and Technology.
Abstract (Originalsprache)
Background
Progressive multifocal leukoencephalopathy (PML) is a rare, often fatal demyelinating disease caused by JC virus reactivation in immunocompromised patients. With the increasing use of immunosuppressants and biologics, PML reporting in non-HIV populations is rising. This study aimed to evaluate drug-associated PML reporting signals using real-world pharmacovigilance data.
Methods
We analyzed FAERS database from 2004Q1 to 2024Q4. We identified PML reports via MedDRA Terms and manual validation. Four algorithms (ROR, PRR, BCPNN, MGPS) were jointly applied, with drugs showing signals across all four defined as high-risk.
Results
7,244 PML reports involving 298 drugs were identified; 72 drugs showed consistent signals, predominantly immunomodulators (e.g., natalizumab, rituximab), antineoplastics, and biologics. High-risk indications included multiple sclerosis, lymphoma, autoimmune diseases, and organ transplantation. PML reporting increased substantially in non-HIV populations. Time-to -reporting varied widely (49–1343days). Over one-third of reports were associated with life-threatening outcomes or death.
Conclusions
This analysis identified 72 drugs with consistent PML reporting signals. However, these findings represent statistical associations in spontaneous reports, not causal relationships or true incidence rates. Inherent limitations—including underreporting, incomplete medication histories, and lack of exposure denominators—require cautious interpretation. Prospective validation studies are essential to establish causality and quantify absolute risks.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Tongji Shanxi Hospital, Taiyuan, China.
ORCID-Profile: Lijuan Shangguan
Förderung
- Shanxi Provincial Department of Science and Technology
Zitieren
APA
Wang, H., Li, X., & Shangguan, L. (2026). Disproportionality analysis of drug-associated progressive multifocal leukoencephalopathy using spontaneous reports: A 20-year signal detection study based on the FAERS database. PLOS One, 21(2), e0341855. https://doi.org/10.1371/journal.pone.0341855
Vancouver
Wang H, Li X, Shangguan L. Disproportionality analysis of drug-associated progressive multifocal leukoencephalopathy using spontaneous reports: A 20-year signal detection study based on the FAERS database. PLOS One. 2026;21(2):e0341855. doi:10.1371/journal.pone.0341855
BibTeX
@article{Wang2026,
author = {Wang, Hailong and Li, Xinyi and Shangguan, Lijuan},
title = {Disproportionality analysis of drug-associated progressive multifocal leukoencephalopathy using spontaneous reports: A 20-year signal detection study based on the FAERS database},
journal = {PLOS One},
year = {2026},
volume = {21},
number = {2},
pages = {e0341855},
doi = {10.1371/journal.pone.0341855}
}
EUVIMED